Peter Bains

Peter Bains returned to Syngene International as Managing Director & Chief Executive Officer effective April 1, 2025, after serving as Group CEO of Biocon, the company's parent, starting in September 2023. Bains holds a bachelor's degree in Science (Combined honours in Zoology and Physiology) from University of Sheffield, United Kingdom, and has over three decades of experience in the global biopharmaceutical industry.

Previously, he served as the CEO of Syngene International from June 2010 to March 2016 and was instrumental in its successful public listing in 2015. Before his recent appointment as Group CEO of Biocon in September 2023, he also served as the CEO of Sosei Group (now Nxera Pharma), a Japanese-listed biopharmaceutical company. Prior to these roles, Bains had a distinguished 23-year career at GlaxoSmithKline (GSK), where he held several senior positions, including Head of Global Marketing and Senior Vice President of Commercial Development for GSK's International region.

Bains brings extensive experience in Biopharmaceuticals across business and technology segmentation (Biotech, Vaccines, Branded Generics, Life Sciences, CRO). He is currently the Non-Executive Director on the Board of Indivior PLC, a UK FTSE-listed pharmaceuticals company; MiNA Therapeutics, a privately held UK biotech company and world leader in small activating RNA technology; and Apterna, a privately held UK biotech engaged in aptamer discovery, and serves as Non-Executive Chairman of ILC Therapeutics, a privately held Scottish biotechnology company.

Career History

• Group CEO, Biocon (September 2023 – April 2025)
• CEO, Sosei Group/Nxera Pharma, Japanese-listed biopharmaceutical company
• CEO, Syngene International Limited (2010–2016), led company to IPO in 2015
• GlaxoSmithKline (GSK) – 23-year career including Head of Global Marketing and Senior Vice President of Commercial Development for International region

What Peter Bains could bring to his renewed role as CEO of Syngene International: His intimate familiarity with Syngene's operations, culture, and strategic direction, having led its transformation from a private company to a public listed entity in 2015, positions him uniquely to drive continued growth. His recent experience as Group CEO at parent company Biocon demonstrates his ability to maximize synergies across multiple operating entities, while his 23-year tenure at GlaxoSmithKline and leadership of Sosei Group provide deep expertise in international pharmaceutical markets and commercial strategy across developed and emerging markets.

This is an automatically generated Light profile created by Executive Moves editorial systems from verified public announcements. Information is kept deliberately concise until the page is claimed and enriched.